ALIGOS THERAPEUTICS INC (ALGS)
US01626L1052 - Common Stock
Overall ALGS gets a fundamental rating of 2 out of 10. We evaluated ALGS against 565 industry peers in the Biotechnology industry. While ALGS seems to be doing ok healthwise, there are quite some concerns on its profitability. ALGS does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year ALGS has reported negative net income.
ALGS had a negative operating cash flow in the past year.
In the past 5 years ALGS always reported negative net income.
ALGS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -87.03%, ALGS is doing worse than 71.71% of the companies in the same industry.
ALGS has a Return On Equity of -153.61%. This is in the lower half of the industry: ALGS underperforms 64.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -87.03% | ||
| ROE | -153.61% | ||
| ROIC | N/A |
ROA(3y)-59.28%
ROA(5y)-50.89%
ROE(3y)-85.72%
ROE(5y)-70.21%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ALGS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ALGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALGS has been reduced compared to 1 year ago.
ALGS has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALGS has an improved debt to assets ratio.
2.2 Solvency
ALGS has an Altman-Z score of -8.91. This is a bad value and indicates that ALGS is not financially healthy and even has some risk of bankruptcy.
ALGS has a worse Altman-Z score (-8.91) than 71.89% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ALGS is not too dependend on debt financing.
ALGS has a Debt to Equity ratio (0.00) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.91 |
ROIC/WACCN/A
WACC10.91%
2.3 Liquidity
A Current Ratio of 3.81 indicates that ALGS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.81, ALGS is in line with its industry, outperforming 45.20% of the companies in the same industry.
A Quick Ratio of 3.81 indicates that ALGS has no problem at all paying its short term obligations.
ALGS has a Quick ratio (3.81) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.81 | ||
| Quick Ratio | 3.81 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 71.77% over the past year.
The Revenue for ALGS has decreased by -63.41% in the past year. This is quite bad
EPS 1Y (TTM)71.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.05%
Revenue 1Y (TTM)-63.41%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-60.82%
3.2 Future
ALGS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.19% yearly.
Based on estimates for the next years, ALGS will show a very strong growth in Revenue. The Revenue will grow by 75.34% on average per year.
EPS Next Y72.97%
EPS Next 2Y30.16%
EPS Next 3Y18.47%
EPS Next 5Y13.19%
Revenue Next Year-74.03%
Revenue Next 2Y-69.6%
Revenue Next 3Y-25.99%
Revenue Next 5Y75.34%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
ALGS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALGS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ALGS's earnings are expected to grow with 18.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.16%
EPS Next 3Y18.47%
5. Dividend
5.1 Amount
ALGS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALIGOS THERAPEUTICS INC
NASDAQ:ALGS (12/20/2024, 8:00:00 PM)
After market: 40.3388 +0.5 (+1.25%)39.84
+1.49 (+3.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners65.59%
Inst Owner Change-71.93%
Ins Owners3.75%
Ins Owner Change0%
Market Cap143.03M
Analysts84.44
Price Target68.85 (72.82%)
Short Float %9.96%
Short Ratio0.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.03%
Min EPS beat(2)-39.56%
Max EPS beat(2)119.61%
EPS beat(4)2
Avg EPS beat(4)21.66%
Min EPS beat(4)-39.56%
Max EPS beat(4)119.61%
EPS beat(8)4
Avg EPS beat(8)12.97%
EPS beat(12)6
Avg EPS beat(12)11.81%
EPS beat(16)9
Avg EPS beat(16)8.85%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-34.68%
PT rev (3m)-37.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1287.04%
EPS NY rev (1m)-56.89%
EPS NY rev (3m)-59.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)12.72%
Revenue NY rev (3m)38.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 23.85 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.86 | ||
| P/tB | 2.86 | ||
| EV/EBITDA | N/A |
EPS(TTM)-13.27
EYN/A
EPS(NY)-12.16
Fwd EYN/A
FCF(TTM)-23.71
FCFYN/A
OCF(TTM)-23.68
OCFYN/A
SpS1.67
BVpS13.95
TBVpS13.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -87.03% | ||
| ROE | -153.61% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-59.28%
ROA(5y)-50.89%
ROE(3y)-85.72%
ROE(5y)-70.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 9.45% | ||
| Cap/Sales | 1.85% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.81 | ||
| Quick Ratio | 3.81 | ||
| Altman-Z | -8.91 |
F-Score3
WACC10.91%
ROIC/WACCN/A
Cap/Depr(3y)23.79%
Cap/Depr(5y)53.57%
Cap/Sales(3y)9.1%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.05%
EPS Next Y72.97%
EPS Next 2Y30.16%
EPS Next 3Y18.47%
EPS Next 5Y13.19%
Revenue 1Y (TTM)-63.41%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-60.82%
Revenue Next Year-74.03%
Revenue Next 2Y-69.6%
Revenue Next 3Y-25.99%
Revenue Next 5Y75.34%
EBIT growth 1Y-21.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.08%
OCF growth 3YN/A
OCF growth 5YN/A